CoChat
Sign Up
Cited by 130Lipoproteins and Cardiovascular HealthLipid metabolism and disordersCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Hypertriglyceridemia: a contraindication to the use of bile acid binding resins.

Crouse, John R.·1987·The American Journal of Medicine
DOI 10.1016/0002-9343(87)90692-9
Open this paper in CoChat — free account

Abstract

Bile acid binding resins are indicated for treatment of elevated plasma low-density lipoprotein cholesterol concentrations. In normoglyceridemic patients, plasma concentrations of low-density lipoprotein cholesterol and total cholesterol are closely linked, and for this reason resin treatment of elevated total cholesterol levels in these patients is rational and warranted. Hypertriglyceridemic patients may also have elevated total cholesterol concentrations, and several such patients have been treated with resin. However, resin therapy in these patients is hazardous, since the elevated cholesterol level mainly results from increased plasma concentrations of very-low-density lipoproteins or chylomicrons rather than low-density lipoproteins. In these patients, resin treatment has either no effect or an adverse effect on plasma triglyceride and cholesterol concentrations. The data presented show that fewer than 5 percent of patients whose total plasma triglyceride concentration exceeded 500 mg/dl had elevated low-density lipoprotein cholesterol concentrations, irrespective of total plasma cholesterol concentrations, and no patient whose plasma triglyceride concentration exceeded 1,000 mg/dl had elevated low-density lipoprotein cholesterol levels. Treatment with bile acid binding resins in hypercholesterolemic patients is contraindicated in the presence of hypertriglyceridemia.

Overview

Integrity signals

Registry

Crossref · 10.1016/0002-9343(87)90692-9

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Patients with normal baseline triglyceride levels experience minimal triglyceride increases with bile acid sequestrant therapy, but those with moderate hypertriglyceridemia (triglycerides >200 mg/dl) may experience substantial further elevation.

    “Patients with normal baseline triglyceride levels experience minimal triglyceride increases with bile acid sequestrant therapy, but those with moderate hypertriglyceridemia (triglycerides Ͼ 200 mg/dl) may experience substantial further elevation (113).”

    From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [113]

  • Bile acid sequestrants (cholestyramine, colestipol, colesevelam) can worsen hypertriglyceridemia.

    “Bile acid sequestrants (cholestyramine, colestipol, colesevelam) can worsen hypertriglyceridemia and are contraindicated in patients with severe hypertriglyceridemia (Ͼ1000 mg/dl) and in patients with dysbetalipoproteinemia.”

    From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [113]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. 1984, 251, 351
  2. 1985, 253, 2080

Cited by

Sorted by citations

Related

Metadata

Authors
Crouse, J. R.
Affiliations
Atrium Health Wake Forest Baptist (US)
Corresponding author
Crouse, John R.
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
1987-08
Volume
83
Issue
2
Pages
243-248
ISSN
0002-9343 (ISSN-L)
DOI
10.1016/0002-9343(87)90692-9
OpenAlex
W2148563587
Cited by
130
References
20
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 5 · 2016: 3 · 2015: 7 · 2014: 4 · 2013: 8 · 2012: 5
FWCI
5.95
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The American Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (HL-01472, HL 14164)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
hypertriglyceridemia, bile acid sequestrants, LDL cholesterol, total cholesterol, VLDL, chylomicrons, hypercholesterolemia, contraindications, lipid-lowering therapy
MeSH terms
Cholesterol, Cholestyramine Resin, Colestipol, Drug Evaluation, Female, Humans, Hypercholesterolemia, Hyperlipidemias, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Polyamines, Time Factors, Triglycerides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review